Phenotypic and functional heterogeneity arise among cancer cells within the same tumour
as a consequence of genetic change, environmental differences and reversible changes in …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative expansion of transformed,
primitive hematopoietic progenitor cells. It involves myeloid, monocytic, erythroid …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Cancer arises through the sequential accumulation of mutations in oncogenes and tumor
suppressor genes. However, how many such mutations are required for a normal human …

There is a lack of effective predictive biomarkers to precisely assign optimal therapy to
cancer patients. While most efforts are directed at inferring drug response phenotype based …

Background BCR-ABL is a constitutively activated tyrosine kinase that causes chronic
myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia
demonstrate that many patients with advanced stage disease respond initially but then …

The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the
introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML …